Korea Market Roundup: Remedi IPO Surges 30%, NK Renews ¥3B Buyback, G마켓 All-In on Coca-Cola

The Quick Take

• Korean X-ray tech company Remedi surged 30%+ above its IPO price on its first day of trading on KOSDAQ
• NK (엔케이) renewed its ¥3 billion share buyback trust for shareholder value enhancement through January 2027
• G마켓 launched a one-day brand promotion concentrating its marketing power on Coca-Cola across multiple product lines

Korea's equity market delivered several noteworthy corporate events on July 13, 2026. The most prominent mover was Remedi, a KOSDAQ-listed X-ray technology company specializing in low-dose, compact, high-resolution X-ray systems, which surged more than 30% above its IPO price of KRW 20,700 on its first day of trading — opening at KRW 27,050 in early morning trade. The debut performance reflects strong domestic investor appetite for medical technology companies with proprietary imaging technology, aligning with global trends toward radiation dose reduction in clinical imaging. Remedi's opening pop validates the recent KOSDAQ IPO market's willingness to award premium multiples to niche medtech innovators with defensible IP positions.

On the shareholder returns front, NK (엔케이) announced the renewal of its KRW 3 billion share buyback trust contract, following the expiry of an identical-size program initiated in December 2024. The back-to-back buyback renewals signal management's commitment to sustaining share price support and returning capital to investors, a strategy gaining traction among mid-cap Korean industrials seeking to narrow the 'Korea discount' valuation gap. In the e-commerce sector, G마켓 executed its periodic 'One Day Brand' promotion with Coca-Cola as the featured partner, concentrating its full marketing capabilities on Coca-Cola products including Sprite, Fanta, and Powerade — illustrating the competitive dynamics between Korean e-commerce platforms for premium brand partnership revenue.

Forward signals for Korea's corporate calendar include tracking IPO pipeline companies in the medical device and semiconductor sectors for post-debut performance patterns similar to Remedi's strong opening. For NK's share buyback strategy, the critical variable is whether buyback purchases will be executed in the open market (visible in daily trading data) or through off-market mechanisms. The macro variable for Korean equity markets overall is the semiconductor sector's ability to stabilize following SK Hynix's record decline and KOSPI circuit breaker activation — if the broader index recovers, mid-cap names like Remedi and NK may benefit from improved market sentiment flowing into smaller-cap names after the blue-chip stabilization.

Synthesized from 4 sources.